{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-296190","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-07-06T20:11:47+00:00","discovered_at":"2026-07-06T20:13:03.311378+00:00","generated_at":"2026-07-06T20:13:12.565684+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Kalaris Therapeutics announces director resignation and election of Laurie Keating","bullets":["Morana Jovan-Embiricos resigned from board and audit committee effective July 3, 2026; no disagreement with company.","Laurie Keating elected as Class I director effective August 1, 2026, and appointed to audit committee.","Keating receives option for 18,000 shares vesting over 3 years, annual cash $40,000 board plus $7,500 audit committee.","Keating will enter standard indemnification agreement; compensation per non-employee director policy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-296190","json":"https://secwatch.observer/filing/0001193125-26-296190.json","markdown":"https://secwatch.observer/filing/0001193125-26-296190.md","text":"https://secwatch.observer/filing/0001193125-26-296190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/0001193125-26-296190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/d34897d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T20:13:12.565684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0adc578b0d","claim":"Laurie Keating was elected as Director at Kalaris Therapeutics, Inc..","evidence_excerpt":"On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/0001193125-26-296190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"23293d839c","claim":"Morana Jovan-Embiricos resigned as Director at Kalaris Therapeutics, Inc..","evidence_excerpt":"On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/0001193125-26-296190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}